Coherus BioSciences (CHRS) Reports Q3 Loss of $1.79
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.40 -1.41%
Revenue Growth %: +91.8%
Financial Fact:
Gain from sale of office premises: 0
Today's EPS Names:
PLCE, COE, JVA, More
Revenue Growth %: +91.8%
Financial Fact:
Gain from sale of office premises: 0
Today's EPS Names:
PLCE, COE, JVA, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q3 EPS of ($1.79), versus ($6.23) reported last year. Revenue for the quarter came in at $16.1 million, versus $500 thousand reported last year.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nvidia pitches Vera CPU to Chinese clients with August delivery target
- Restoration Hardware (RH) PT Raised to $130 at Stifel After Q1 Earnings
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
